Status:
UNKNOWN
Evaluation of Von Willebrand Factor as a Marker For Early Diagnosis of Acute Respiratory Distress Syndrome (A.R.D.S) in Comparison to Interleukin 6 [IL-6]
Lead Sponsor:
Ain Shams University
Conditions:
ARDS, Human
Eligibility:
All Genders
18-80 years
Brief Summary
In this prospective study of 60patients, we tested the hypothesis That markedly elevated levels of plasma von Willebrand factor (VWF) a marker of endothelial cell injury might predict the development ...
Eligibility Criteria
Inclusion
- Patients between 18 and 80 years old of both sexes.
- risk factor for development of acute respiratory distress syndrome or acute lung injury either by:
- Direct lung injury includes: Severe pneumonia (infection), Breathing a vomited stomach contents (aspiration), Breathing harmful fumes or smoke, severe trauma to the chest or other accident that bruises the lungs.
- Indirect lung injury includes: sepsis, Severe injury or trauma with shock, blood transfusions , drug overdose acute pancreatitis, fracture of the long bones, near drowning ,anaphylaxis, uremia, fat embolus , and intracranial insult.
Exclusion
- (1) pregnancy;
- (2) a preexisting medical condition with a life expectancy less than 3 months
- (3) evidence of cardiogenic pulmonary edema
- (4) age under 18 years old or above 80 years old
- (5) late stages of liver cell failure, renal failure
- (6) severe myocardial infarction
- (7) deep coma.
Key Trial Info
Start Date :
March 21 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
September 20 2021
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT04317469
Start Date
March 21 2020
End Date
September 20 2021
Last Update
March 23 2020
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.